Analyst ratings and price targets can significantly influence investor sentiment and trading behavior. In this case, RBC Capital's reiteration of a 'Sector Perform' rating and a $100 price target on Biomarin Pharmaceutical (BMRN) could potentially impact the stock's performance in the short term. However, as this is a reiteration and not a change, the impact may be neutral.